TF2
/ Gilead
- LARVOL DELTA
Home
Next
Prev
1 to 19
Of
19
Go to page
1
November 09, 2011
TF2- Small Cell Lung Cancer Radio Immunotherapy
(clinicaltrials.gov)
- P1/2; N=33; Recruiting; Sponsor: Centre René Gauducheau; Not yet recruiting ➔ Recruiting
Clinical • Enrollment open • Lung Cancer • Neuroendocrine Tumor • Non Small Cell Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor • EGFR
April 12, 2016
TF2- Small Cell Lung Cancer Radio Immunotherapy
(clinicaltrials.gov)
- P1/2; N=33; Active, not recruiting; Sponsor: Centre René Gauducheau; Recruiting ➔ Active, not recruiting
Clinical • Enrollment closed • Lung Cancer • Neuroendocrine Tumor • Non Small Cell Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor • EGFR
August 31, 2016
TF2- Small Cell Lung Cancer Radio Immunotherapy
(clinicaltrials.gov)
- P1/2; N=18; Completed; Sponsor: Centre René Gauducheau; Active, not recruiting ➔ Completed; N=33 ➔ 18; Trial primary completion date: Jun 2017 ➔ Apr 2016
Clinical • Enrollment change • Trial completion • Trial primary completion date • Lung Cancer • Neuroendocrine Tumor • Non Small Cell Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor • EGFR
September 15, 2015
TF2- Small Cell Lung Cancer Radio Immunotherapy
(clinicaltrials.gov)
- P1/2; N=33; Recruiting; Sponsor: Centre René Gauducheau; Trial primary completion date: Jun 2015 ➔ Jun 2017
Clinical • Trial primary completion date • Lung Cancer • Neuroendocrine Tumor • Non Small Cell Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor • EGFR
December 07, 2020
Study of TF2 Carcinoembryonic Antigen (CEA) Antibody in Patients With Metastatic Colorectal Cancer
(clinicaltrials.gov)
- P1; N=0; Withdrawn; Sponsor: Immunomedics, Inc.; N=30 ➔ 0; Terminated ➔ Withdrawn
Clinical • Enrollment change • Trial withdrawal • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Rheumatoid Arthritis • Solid Tumor
July 10, 2020
Relative Bioavailability (rBA) of Evobrutinib Intended Commercial and Clinical Tablets, and Effect of Food on Intended Commercial Tablets
(clinicaltrials.gov)
- P1; N=18; Completed; Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany; Recruiting ➔ Completed
Clinical • Trial completion
June 11, 2020
Relative Bioavailability (rBA) of Evobrutinib Intended Commercial and Clinical Tablets, and Effect of Food on Intended Commercial Tablets
(clinicaltrials.gov)
- P1; N=18; Recruiting; Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany; Not yet recruiting ➔ Recruiting
Clinical • Enrollment open
July 23, 2016
Immunomedics: Commercial Update
(Immunomedics)
- Anticipated patent expiry in US, Europe and Japan in 2026
Anticipated patent expiry • Oncology
January 19, 2017
iTEP-CMT: ImmunoTEP for Patients With Medullary Thyroid Carcinoma.
(clinicaltrials.gov)
- P1/2; N=25; Completed; Sponsor: Nantes University Hospital; Recruiting ➔ Completed
Trial completion • Biosimilar • Immunology • Oncology • Thyroid Cancer
March 18, 2020
Relative Bioavailability (rBA) of Evobrutinib Intended Commercial and Clinical Tablets, and Effect of Food on Intended Commercial Tablets
(clinicaltrials.gov)
- P1; N=18; Not yet recruiting; Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Clinical • New P1 trial
July 10, 2019
A Study in Healthy Men to Test if Taking Different Formulations of BI 1358894 With or Without Food Influences the Amount of BI 1358894 in the Blood
(clinicaltrials.gov)
- P1; N=24; Completed; Sponsor: Boehringer Ingelheim; Active, not recruiting ➔ Completed
Clinical • Trial completion
June 04, 2019
A Study in Healthy People to Test if Taking Different Formulations of BI 425809 Tablets Influences the Amount of BI 425809 in the Blood
(clinicaltrials.gov)
- P1; N=18; Completed; Sponsor: Boehringer Ingelheim; Active, not recruiting ➔ Completed
Clinical • Trial completion
May 16, 2019
A Study in Healthy Men to Test if Taking Different Formulations of BI 1358894 With or Without Food Influences the Amount of BI 1358894 in the Blood
(clinicaltrials.gov)
- P1; N=24; Active, not recruiting; Sponsor: Boehringer Ingelheim; Recruiting ➔ Active, not recruiting
Clinical • Enrollment closed
April 11, 2019
A Study in Healthy Men to Test if Taking Different Formulations of BI 1358894 With or Without Food Influences the Amount of BI 1358894 in the Blood
(clinicaltrials.gov)
- P1; N=24; Recruiting; Sponsor: Boehringer Ingelheim; Not yet recruiting ➔ Recruiting
Clinical • Enrollment open
March 22, 2019
A Study in Healthy People to Test if Taking Different Formulations of BI 425809 Tablets Influences the Amount of BI 425809 in the Blood
(clinicaltrials.gov)
- P1; N=18; Active, not recruiting; Sponsor: Boehringer Ingelheim; Recruiting ➔ Active, not recruiting
Clinical • Enrollment closed
March 27, 2019
A Study in Healthy Men to Test if Taking Different Formulations of BI 1358894 With or Without Food Influences the Amount of BI 1358894 in the Blood
(clinicaltrials.gov)
- P1; N=24; Not yet recruiting; Sponsor: Boehringer Ingelheim
Clinical • New P1 trial
March 14, 2019
Bioequivalence of Tablet Formulation 3 (TF3) and Tablet Formulation 2 (TF2) and Effect of Food on the Pharmacokinetics (PK) of Tepotinib
(clinicaltrials.gov)
- P1; N=65; Completed; Sponsor: Merck KGaA, Darmstadt, Germany; Not yet recruiting ➔ Completed
Clinical • Trial completion
February 15, 2019
A Study in Healthy People to Test if Taking Different Formulations of BI 425809 Tablets Influences the Amount of BI 425809 in the Blood
(clinicaltrials.gov)
- P1; N=18; Recruiting; Sponsor: Boehringer Ingelheim; Not yet recruiting ➔ Recruiting
Clinical • Enrollment open
January 25, 2019
A Study in Healthy People to Test if Taking Different Formulations of BI 425809 Tablets Influences the Amount of BI 425809 in the Blood
(clinicaltrials.gov)
- P1; N=18; Not yet recruiting; Sponsor: Boehringer Ingelheim
Clinical • New P1 trial
1 to 19
Of
19
Go to page
1